Filter Results:
(296)
Show Results For
- All HBS Web
(694)
- People (2)
- News (224)
- Research (296)
- Events (4)
- Multimedia (12)
- Faculty Publications (181)
Show Results For
- All HBS Web
(694)
- People (2)
- News (224)
- Research (296)
- Events (4)
- Multimedia (12)
- Faculty Publications (181)
Sort by
- March 2008 (Revised June 2008)
- Case
The Broad Institute: Applying the Power of Genomics to Medicine
By: Vicki L. Sato and Rachel Gordon
In June 2003, Harvard University and MIT announced an unprecedented partnership to create a biomedical institute, The Broad Institute. The culture of the Broad centered on science, and those involved considered it to be at the edge of the scientific frontier. In just... View Details
Keywords: Education; Health Care and Treatment; Innovation Leadership; Growth and Development Strategy; Organizational Culture; Partners and Partnerships; Research and Development; Genetics
Sato, Vicki L., and Rachel Gordon. "The Broad Institute: Applying the Power of Genomics to Medicine." Harvard Business School Case 608-114, March 2008. (Revised June 2008.)
- July 2002 (Revised August 2002)
- Case
Washington Hospital Center (D): Emergency Medicine After September 11
By: Rosabeth M. Kanter and Michelle Heskett
The all-risks-ready emergency room prototype project becomes widely accepted as a need after September 11, 2001. The already operational medical informatics system, Insight, comes under heavy demand after its strong performance during crises and is noticed by various... View Details
- Article
How To Build A Life: Love Is Medicine for Fear
By: Arthur C. Brooks
Brooks, Arthur C. "How to Build a Life: Love Is Medicine for Fear." The Atlantic (July 16, 2020).
- April 2022
- Article
AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care
By: Ariel Dora Stern, Avi Goldfarb, Timo Minssen and W. Nicholson Price II
Despite enthusiasm about the potential to apply artificial intelligence (AI) to medicine and health care delivery, adoption remains tepid, even for the most compelling technologies. In this article, the authors focus on one set of challenges to AI adoption: those... View Details
Keywords: Artificial Intelligence; Medicine; Health Care and Treatment; Legal Liability; Insurance; Technology Adoption; AI and Machine Learning
Stern, Ariel Dora, Avi Goldfarb, Timo Minssen, and W. Nicholson Price II. "AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care." NEJM Catalyst Innovations in Care Delivery 3, no. 4 (April 2022).
- October 4, 2018
- Article
Precision Medicine Needs a Business Mindset in Order to Flourish
By: Richard G. Hamermesh and Kathryn E. Giusti
Hamermesh, Richard G., and Kathryn E. Giusti. "Precision Medicine Needs a Business Mindset in Order to Flourish." STAT (October 4, 2018).
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 2021
- Working Paper
Regulatory Approval and Expanded Market Size
By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality... View Details
Keywords: New Medicines; Regulatory Approval; Health Care and Treatment; Research and Development; Governing Rules, Regulations, and Reforms; Markets; Expansion; Pharmaceutical Industry
Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.
- September 2020 (Revised February 2021)
- Case
Pricing the Priceless: Covering Transformational Medicines at Harvard Pilgrim Health Plan
By: Amitabh Chandra and Sofia Guerra
Chandra, Amitabh, and Sofia Guerra. "Pricing the Priceless: Covering Transformational Medicines at Harvard Pilgrim Health Plan." Harvard Business School Case 621-059, September 2020. (Revised February 2021.)
- fall 2002
- Article
Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial." Chemical Heritage, no. 20 (fall 2002): 12–13, 28–33.
- November 12, 2018
- Article
Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology
By: Richard G. Hamermesh and Kathy Giusti
Hamermesh, Richard G., and Kathy Giusti. "Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology." Fortune.com (November 12, 2018).
- Working Paper
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,... View Details
Keywords: Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are... View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- Article
The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making
By: Joshua Lev Krieger, Fiona Murray, J. Scott Roberts and Robert C. Green
Krieger, Joshua Lev, Fiona Murray, J. Scott Roberts, and Robert C. Green. "The Impact of Personal Genomics on Risk Perceptions and Medical Decision-Making." Nature Biotechnology 34, no. 9 (September 2016): 912–918.
- 2008
- Other Unpublished Work
Evidence-Based Medicine and the Changing Nature of Healthcare: 2007 IOM Annual Meeting Summary
Keywords: Health
Porter, Michael E. "Evidence-Based Medicine and the Changing Nature of Healthcare: 2007 IOM Annual Meeting Summary." Institute of Medicine, Washington, DC, October 2008.
- March 2010 (Revised August 2012)
- Supplement
WellSpace Treatment Centers for Complementary and Alternative Medicine (B) - The Marino Center
The Marino Center provides complementary traditional and alternative health care services. It wants to grow, but how and where? View Details
- November 2012 (Revised January 2013)
- Case
Companion Diagnostics: Uncertainties for Approval and Reimbursement
By: Richard G. Hamermesh, Norman C. Selby and Phillip Andrews
The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory... View Details
Keywords: Models Of Reimbursement; Personalized Medicine; Regulation; Healthcare Reform; Health Care and Treatment; Health Industry; United States
Hamermesh, Richard G., Norman C. Selby, and Phillip Andrews. "Companion Diagnostics: Uncertainties for Approval and Reimbursement." Harvard Business School Case 813-037, November 2012. (Revised January 2013.)
- Article
One Obstacle to Curing Cancer: Patient Data Isn't Shared
By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For... View Details
Keywords: Healthcare; Technological And Scientific Innovation; Cancer Care In The U.S.; Cancer Treatment; Precision Medicine; Personalized Medicine; Data Sharing; Technological Innovation; Analytics and Data Science; Health Disorders; Medical Specialties; Research and Development; Customization and Personalization; Health Industry; United States
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
- 01 Jun 2020
- Working Paper Summaries
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
- Article
Cybersecurity Features of Digital Medical Devices: An Analysis of FDA Product Summaries
By: Ariel Dora Stern, William J. Gordon, Adam B. Landman and Daniel B. Kramer
Objectives:
To more clearly define the landscape of digital medical devices subject to U.S. Food and Drug Administration (FDA) oversight, this analysis leverages publicly available regulatory documents to characterise the prevalence and trends of software and... View Details
To more clearly define the landscape of digital medical devices subject to U.S. Food and Drug Administration (FDA) oversight, this analysis leverages publicly available regulatory documents to characterise the prevalence and trends of software and... View Details
Keywords: Digital; Medicine; FDA; Health Care and Treatment; Applications and Software; Safety; Cybersecurity; Medical Devices and Supplies Industry
Stern, Ariel Dora, William J. Gordon, Adam B. Landman, and Daniel B. Kramer. "Cybersecurity Features of Digital Medical Devices: An Analysis of FDA Product Summaries." BMJ Open 9, no. 6 (June 2019).
- April 2021
- Case
ClearChoice Dental Implant Centers
By: Robert S. Kaplan, Ashiana Jivraj and Jane Barrow
The case illustrates the application of value-based health care to dental medicine. ClearChoice Dental Implant Centers was a rapidly-growing network of dentist-owned independent implant clinics. The targeted market included 23 million people, 15% of the US adult... View Details
Keywords: Value-based Health Care; Dental Medicine; Growth and Development Strategy; Expansion; Business Strategy; Customer Value and Value Chain; Customer Focus and Relationships; Health Industry; United States
Kaplan, Robert S., Ashiana Jivraj, and Jane Barrow. "ClearChoice Dental Implant Centers." Harvard Business School Case 121-082, April 2021.